Pharmability Completes GMP Release of TIR-C Clinical Trial Material
Pharmability has completed the Good Manufacturing Practice (GMP) release of clinical trial material for its TIR-C drug candidate. The material is ready for use in the upcoming Phase Ib trial.
Pharmability announced the completion of Good Manufacturing Practice (GMP) manufacturing and release of clinical trial material for its TIR-C drug. This milestone signifies the material is ready for use in the company's upcoming Phase Ib trial evaluating TIR-C for atopic dermatitis.
The manufactured batch includes both the active TIR-C compound and a matching placebo, providing the necessary investigational product to commence patient enrollment. Zelmic, a contract development and manufacturing organization (CDMO), was responsible for the formulation and production of the material.
Adherence to GMP standards ensures the quality, safety, and efficacy of the drug substance. This regulatory compliance is critical for any pharmaceutical product intended for human clinical trials.
The Phase Ib trial will assess the safety and tolerability of TIR-C in patients diagnosed with atopic dermatitis. The successful GMP release of the trial material is a prerequisite for initiating this patient study.